Related Experiment Video

Updated: Mar 11, 2026

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA
12:18

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA

Published on: February 9, 2011

23.7K

Community-acquired Staphylococcus aureus bacteremia in children: a cohort study for 2010-2014

Guadalupe Pérez1, Soledad Martiren2, Vanesa Reijtman3

  • 1Servicio de Control Epidemiológico e Infectología, Hospital de Pediatría "Prof. Dr. Juan P. Garrahan", Ciudad Autónoma de Buenos Aires, Argentina. guaperez@hotmail.com.

Archivos Argentinos De Pediatria
|November 22, 2016
PubMed

Insights

Community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) is a significant pediatric concern. In this cohort, CA-MRSA predominated, particularly in healthy children, and was associated with severe outcomes like ICU admission and death.

Area of Science:

  • Pediatric Infectious Diseases
  • Microbiology
  • Epidemiology

Background:

  • Community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) presents a substantial challenge in pediatric healthcare.
  • Staphylococcus aureus (SA) bacteremia requires ongoing surveillance for antibiotic resistance patterns.

Purpose of the Study:

  • To characterize antibiotic resistance in pediatric SA bacteremia.
  • To compare clinical and microbiological features of SA bacteremia based on methicillin resistance.

Main Methods:

  • Prospective cohort study of 208 children (30 days to 16 years) hospitalized with SA bacteremia.
  • Inclusion criteria focused on community-acquired infections; exclusion criteria addressed recent hospitalizations or healthcare exposures.
  • Comparison of microbiological, demographic, and clinical data stratified by methicillin susceptibility.

Main Results:

  • Methicillin-resistant Staphylococcus aureus (MRSA) was identified in 65% of cases (136/208 children).
  • Clindamycin resistance was observed in 9% of isolates.
  • MRSA bacteremia was associated with higher rates of underlying disease, persistent bacteremia, sepsis, ICU admission, and need for surgery.

Conclusions:

  • MRSA is the predominant pathogen in this pediatric SA bacteremia cohort.
  • CA-MRSA infections were more common in previously healthy children.
  • Severe outcomes, including persistent bacteremia, ICU admission, and mortality, were more frequent in MRSA cases.
Abstract

Keywords:
Community-acquired infectionsMethicillin resistanceStaphylococcus aureus

More Related Videos

Oral Biofilm Sampling for Microbiome Analysis in Healthy Children10:42

Oral Biofilm Sampling for Microbiome Analysis in Healthy Children

Published on: December 31, 2017

18.0K
Development and Assessment of Intracellular Infection Models for Staphylococcus aureus08:32

Development and Assessment of Intracellular Infection Models for Staphylococcus aureus

Published on: January 17, 2025

1.4K

Related Concept Videos

Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
573
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
346
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
306
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
605
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
411